Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue	$ 4,005,000	$ 6,414,000	$ 2,764,000
Operating expenses:
Research and development	13,324,000	11,015,000	15,119,000
General and administrative	12,343,000	7,251,000	8,537,000
Total operating expenses	25,667,000	18,266,000	23,656,000
Operating loss	(21,662,000)	(11,852,000)	(20,892,000)
Other income	2,448,000		1,000
Other income (expense) – related party	1,609,000	(270,000)	827,000
Interest income	1,000	12,000	53,000
Interest expense	(12,000)	(692,000)	(1,827,000)
Loss before income taxes and noncontrolling interest	(17,616,000)	(12,802,000)	(21,838,000)
Income tax provision	115,000	0	100,000
Net loss before noncontrolling interest	(17,731,000)	(12,802,000)	(21,938,000)
Less: net loss attributable to noncontrolling interest	(4,744,000)	(4,303,000)	(8,894,000)
Net loss attributable to vTv Therapeutics Inc.	(12,987,000)	(8,499,000)	(13,044,000)
Net loss attributable to vTv Therapeutics Inc. common shareholders	$ (12,987,000)	$ (8,499,000)	$ (17,913,000)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.21)	$ (0.18)	$ (0.59)
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	60,732,636	47,137,917	30,292,030